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Trajectories of inflammatory biomarkers
over the eighth decade and their
associations with immune cell profiles and
epigenetic ageing
Anna J. Stevenson1,6,7* , Daniel L. McCartney1, Sarah E. Harris1,2, Adele M. Taylor3, Paul Redmond3, John M. Starr2,4,
Qian Zhang5, Allan F. McRae5, Naomi R. Wray5, Tara L. Spires-Jones6,7, Barry W. McColl6,7, Andrew M. McIntosh2,8,
Ian J. Deary2,3 and Riccardo E. Marioni1,2
Abstract
Background: Epigenetic age acceleration (an older methylation age compared to chronological age) correlates
strongly with various age-related morbidities and mortality. Chronic systemic inflammation is thought to be a
hallmark of ageing, but the relationship between an increased epigenetic age and this likely key phenotype of
ageing has not yet been extensively investigated.
Methods: We modelled the trajectories of the inflammatory biomarkers C-reactive protein (CRP; measured using
both a high- and low-sensitivity assay) and interleukin-6 (IL-6) over the eighth decade in the Lothian Birth Cohort 1936.
Using linear mixed models, we investigated the association between CRP and immune cell profiles imputed from the
methylation data and examined the cross-sectional and longitudinal association between the inflammatory biomarkers
and two measures of epigenetic age acceleration, derived from the Horvath and Hannum epigenetic clocks.
Results: We found that low-sensitivity CRP declined, high-sensitivity CRP did not change, and IL-6 increased over time
within the cohort. CRP levels inversely associated with CD8+T cells and CD4+T cells and positively associated with
senescent CD8+T cells, plasmablasts and granulocytes. Cross-sectionally, the Hannum, but not the Horvath, measure of
age acceleration was positively associated with each of the inflammatory biomarkers, including a restricted measure of
CRP (≤ 10mg/L) likely reflecting levels relevant to chronic inflammation.
Conclusions: We found a divergent relationship between inflammation and immune system parameters in older age.
We additionally report the Hannum measure of epigenetic age acceleration associated with an elevated inflammatory
profile cross-sectionally, but not longitudinally.
Keywords: Inflammation, DNA methylation, Epigenetics, Epigenetic age acceleration, Immune cells
Background
Epidemiological studies have long associated ageing with
a progressive move to a chronic inflammatory state, a
phenomenon often referred to as ‘inflammaging’ [1, 2].
This low-grade, and typically sub-acute, elevation of
peripheral pro-inflammatory mediators in the absence of
overt infection is strongly associated with the susceptibility
to, and progression of, many age-associated diseases such
as cancer, type 2 diabetes and Alzheimer’s disease, and is a
key risk factor for mortality [3].
Many studies of inflammation in older adults have
focused on the acute-phase protein C-reactive protein
(CRP) and the pro-inflammatory cytokine interleukin 6
(IL-6), both of which are sensitive biomarkers of low-grade
inflammation. Akin to other biomarkers, inflammatory
mediators can be highly variable, yet much of the research
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into their alterations in ageing has been cross-sectional
[4, 5]. Multiple-time point measurements are critical to
establish the chronicity of inflammatory biomarkers and
their trajectories with age, which in itself is key to unravel-
ling the mechanisms behind the process. Several putative
pathways have been identified as playing a role in chronic
systemic inflammation including increased visceral adiposity,
oxidative stress and telomeric and mitochondrial dysfunc-
tion [6, 7], and genetic studies have produced candidate
polymorphisms associated with the process [8–10]. There
remains, however, a lack of understanding of the aetiology
of chronic inflammation and its relationship with molecular
ageing rates [3, 6].
DNA methylation is an epigenetic mechanism by which
methyl groups are added to the DNA molecule, typically
at cytosine-guanine (CpG) dinucleotides. Chronological
age has been shown to have a significant effect on methy-
lation levels, and as such, several highly accurate DNA
methylation-based biological markers of ageing, or ‘epi-
genetic clocks’, have been proposed [11, 12]. Accelerated
epigenetic ageing, as evinced by a greater methylation age
compared to chronological age, has been linked to various
age-associated health outcomes such as frailty [13], lung
cancer [14] and Parkinson’s disease [15], as well as all-cause
mortality [16, 17]. There have been many diverse applica-
tions of the epigenetic clock to studies of ageing and disease,
but relatively little is known about the relationship between
accelerated epigenetic ageing and a likely key intermediary
process of ageing and age-related morbidity: inflammation.
Investigating such relationships may give further insight into
the molecular aetiology of inflammation and the pathways
that regulate it in the ageing process.
In the current study, we investigate the dynamics of
inflammation across the eighth decade and its relation-
ship with epigenetic age. We established the trajectories
of the inflammatory biomarkers CRP and IL-6 and their
association with imputed immune cells in the Lothian Birth
Cohort 1936 (LBC1936). We then assessed their cross-sec-
tional and longitudinal associations with epigenetic age ac-
celeration, using two widely used measures: intrinsic
epigenetic age acceleration (IEAA) and extrinsic epigenetic
age acceleration (EEAA) (described in the ‘Methods’ sec-
tion). Chronic inflammation is considered to be a pervasive
feature of ageing and, as epigenetic age robustly correlates
with chronological age, we hypothesise that a faster running
epigenetic clock will associate with greater levels of systemic
inflammatory biomarkers.
Results
Baseline cohort demographics
Of the 1091 (543 female; 49.8%) participants recruited at
wave 1, CRP measures (mg/L) were available for 1054 par-
ticipants (mean = 5.26mg/L, SD = 6.68) and epigenetic age
acceleration measures for 906 (IEAA: mean = − 0.465
years, SD = 5.99; EEAA: mean = − 0.319 years, SD = 7.09).
Ninety-five participants were taking anti-inflammatory
medication at baseline (8.7%).
Trajectories of inflammatory biomarkers
Spaghetti plots of the trajectories of both raw and
log-transformed CRP and IL-6 over time are shown in
Fig. 1. Low-sensitivity log(CRP) was found to decline over
the 9 years of follow-up by an average of 0.01 SD per year
(p = 0.004). The slight increase in high-sensitivity log(CRP)
levels over the two waves seen in the plot was not found
to be significant (p = 0.718). log(IL-6) increased with age,
by an average of 0.15 SD per year (p = 2 × 10− 16).
Due to the discrepancy between the trajectories of
the high- and low-sensitivity CRP measures, we repeated
the analysis of the low-sensitivity measure, restricted to the
same time points as were available for the high-sensitivity
measure (waves 2 and 3). Akin to the high-sensitivity
measure, no change was seen over these two waves
(beta = − 0.005, p = 0.836) indicating that the 3-year time
period between waves is perhaps too brief to capture sig-
nificant variations in CRP.
Correlations
Correlations between the inflammatory biomarkers both
within and between waves are presented in Fig. 2. The
high- and low-sensitivity CRP measures correlated strongly
within waves (r ≥ 0.93), and both measures had moderate
intra-wave correlations with IL-6 (r = 0.41–0.45). The low-
sensitivity CRP correlations across the four waves were low
(r = 0.14–0.26). Similar coefficients were seen over the two
waves for the high-sensitivity CRP measure (r = 0.14) and
IL-6 (r = 0.33).
Associations with imputed immune cells
Due to the association between inflammation and
immunosenescence, we examined the dynamics of the
immune cells imputed from the methylation data, and
their association with CRP levels.
We initially established the correlations between both the
high- and low-sensitivity CRP measures and the imputed
cell profiles across the four waves of data (Table 1). There
was no significant difference between the correlation coeffi-
cients of the two measures across the two waves of overlap
(Wilcoxon signed-rank test: wave 2: p = 0.76; wave 3: p =
0.44), and the directions of the coefficients were consistent.
This indicated the lower-sensitivity measure of CRP was
representative, and its use in our analyses was unlikely to
skew results.
All lymphocyte cells declined over time: CD8+T
total (beta = − 0.01 SD/year, p = 4.46 × 10− 7); naïve
CD8+T (beta = − 0.01 SD/year, p = 4.22 × 10− 5); total
CD4+T (beta = − 0.06 SD/year, p = 2 × 10− 16); naïve CD4+T
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(beta =− 0.05 SD/year, p = 2 × 10− 16); NK (beta = − 0.04
SD/year, p = 2 × 10− 16); B (beta = − 0.04 SD/year, p = 2 ×
10− 16). Exhausted/senescent CD8+T cells increased with
age (beta = 0.03 SD/year, p = 1.18 × 10− 14) as did mono-
cytes (beta = 0.06 SD/year, p = 2 × 10− 16), granulocytes
(beta = 0.04 SD/year, p = 2 × 10− 16) and plasmablasts
(beta = 0.08 SD/year, p = 2 × 10− 16) (Fig. 3.)
The baseline associations between the blood cellular
composition and low-sensitivity log(CRP) within the
cohort are presented in Table 2. An inverse association
was observed between CRP and CD8+T cells (total:
beta = − 0.073, p = 0.026; naïve: beta = − 0.142, p = 2.54 ×
10− 5) and CD4+T cells (total: beta = − 0.132, p = 6.74 ×
10− 5, naïve: beta = − 0.072, p = 0.032). A positive associ-
ation was found between CRP and senescent CD8+T cells
(beta = 0.134, p = 3.79 × 10− 5), plasmablasts (beta = 0.148,
p = 1.38 × 10− 5) and granulocyte counts (beta = 0.133, p =
4.17 × 10− 5). No associations were found between log(CRP)
and B cells, NK cells or monocytes. A CRP level of ≤ 10mg/L
is often cited as reflecting the non-acute, chronic in-
flammation, relevant to what has been reported in ageing
[18]. Because of this, we ran a sensitivity analysis excluding
those with CRP > 10mg/L to test if the associations were
altered with more chronic levels of inflammation. Here, the
associations with CD4+T cells, total CD8+T cells and gran-
ulocytes were attenuated, though the coefficients were in
Fig. 1 Spaghetti plots of change in CRP and IL-6 over time. CRP: C-reactive protein; IL-6: interleukin-6; hs: high-sensitivity; ls: low-sensitivity;
log(): log-transformed
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the same direction as previously. All other results remained
the same though with larger p values (Additional file 1).
Associations with age acceleration
We assessed the cross-sectional and longitudinal rela-
tionship between each inflammatory biomarker and
methylation-based age acceleration using IEAA and EEAA
(Table 3). Positive baseline associations were found between
both the low- and high-sensitivity CRP measures and EEAA
(low-sensitivity log(CRP): beta = 0.154, p= 2.48 × 10− 5, high-
sensitivity log(CRP): beta = 0.111, p= 0.004). No baseline
correlations were seen between either CRP measure or
Fig. 2 Heatmap of correlations between inflammatory biomarkers within and across the four waves of data collection. lsCRP was available at all
four waves of data collection; hsCRP and IL-6 were available at waves 2 and 3 only. CRP: C-reactive protein; IL-6: interleukin-6; ls: low-sensitivity;
hs: high-sensitivity
Table 1 Pearson correlations between high- and low-sensitivity CRP measures and imputed immune cell profiles
Wave 1 Wave 2 Wave 3 Wave 4
ls hs ls hs ls hs ls hs
Total CD8+T −0.077 NA − 0.057 −0.041 − 0.053 −0.053 − 0.098 NA
Total CD4+T −0.167 NA −0.104 −0.107 − 0.12 −0.112 − 0.079 NA
Natural killer −0.108 NA −0.067 −0.086 − 0.094 −0.083 − 0.15 NA
B cells −0.093 NA −0.053 −0.029 − 0.084 −0.071 0.006 NA
Senescent CD8+T 0.119 NA 0.077 0.072 0.039 0.044 0.003 NA
Naïve CD8+T −0.068 NA −0.055 −0.054 0.089 0.071 −0.102 NA
Naïve CD4+T −0.066 NA −0.024 −0.022 0.01 0.015 −0.033 NA
Monocytes 0.037 NA 0.099 0.101 0.079 0.087 0.134 NA
Granulocytes 0.192 NA 0.106 0.097 0.146 0.119 0.112 NA
Plasmablasts 0.186 NA 0.133 0.127 0.132 0.119 0.103 NA
ls low-sensitivity CRP, hs high-sensitivity CRP, NA not available
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IEAA (p ≥ 0.087). Neither baseline IEAA nor EEAA
was associated with longitudinal change in log(CRP)
(p ≥ 0.360).
log(IL-6) also showed a positive baseline association
with EEAA (beta = 0.114, p = 0.003) but not with IEAA
(p = 0.563). There was no longitudinal association between
the log(IL-6) measure and either measure of epigenetic age
acceleration (p ≥ 0.392).
We additionally investigated the relationship between
epigenetic age acceleration and log(CRP) in the subset of
the cohort with CRP levels of ≤ 10mg/L, as measured by
the low-sensitivity assay (Table 3). A positive cross-sectional
association was present between EEAA and CRP levels
(beta = 0.129, p= 0.0009). No equivalent association was ob-
served with IEAA (p= 0.081). There were no longitudinal
associations with either measure of epigenetic age acceler-
ation (p ≥ 0.303).
Discussion
In the current study, we found a decline over time in
the serum levels of the inflammatory mediator CRP,
measured using a low-sensitivity assay in LBC1936.
The CRP levels measured from the high-sensitivity
assay did not exhibit similarly significant changes with
Fig. 3 Spaghetti plots of change in imputed immune cell profiles over time
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age, whereas the pro-inflammatory cytokine IL-6 was
found to increase in the cohort across the two waves
of follow-up from age 73 to 76. We found a decline
over time in naïve and total CD8+T cells, naïve and
total CD4+T cells, NK cells and B cells. Congruent
with flow cytometric data, senescent CD8+T cells
were found to increase with age, as did monocytes,
granulocytes and plasmablasts [16]. Negative baseline
associations were found between CRP and both naïve
and total CD8+T cells and CD4+T cells, and positive
associations between CRP and senescent CD8+T cells,
plasmablasts and granulocytes. We report associations
between both high- and low-sensitivity measures of
CRP, IL-6 and a restricted CRP measure (≤ 10 mg/L)
with extrinsic estimates of epigenetic age acceleration.
These findings suggest a higher epigenetic age is associ-
ated with an increased inflammatory profile, in relation to
both general inflammation, and to levels likely reflecting
chronic, low-grade inflammation.
The dynamics of the low-sensitivity CRP in the cohort
were paradoxical to what we might have predicted in a
longitudinal study of ageing as previous studies have
shown a progressive increase in CRP levels as a function
of age [7, 19]. Furthermore, IL-6 is a major driving factor
in CRP production, yet, despite observing a rise in the
cytokine over waves 2 and 3, no corresponding increase is
seen in the low-sensitivity CRP levels; in fact, the opposite
is seen. These findings may be due to the poor sensitivity
of the assay used to quantify the CRP levels, particularly at
the lower range of values, though levels were found to
correlate strongly with those from the more sensitive
measure. It is possible that a disruption in the pathway of
CRP production impacted our results. CRP is of hepatic
origin and it is feasible that impaired liver function, which
is common in older adults, influenced its production
within individuals in the cohort. Similarly, CRP produc-
tion is influenced by other cytokines alongside IL-6, such
as IL-1 and IL-17, and as these were not measured in the
current study, their potential influence is unknown [20].
Another explanation may lie in the fact the LBC1936 is
a largely healthy older ageing cohort. Multiple chronic
conditions are common in elderly populations, and our
results may reflect a more successful ageing process revealed
through more static or declining CRP levels. Though part of
the innate immune system, inflammation may be a
somewhat adaptive response in older age and research
has indicated it might confer protection when under
tight control [18, 21]. Indeed, centenarians often have
signs of systemic inflammation but are not afflicted by
age-associated diseases [22]. It is often argued that inflam-
mation is beneficial in neutralising harmful stimuli in early
life but becomes detrimental in older age; however, it may
be that optimum levels of inflammation change, but con-
tinue to exist, in old age and excessive, insufficient, or
Table 2 Baseline associations between low-sensitivity C-reactive
protein and imputed immune cell profiles
Standardised beta SE p
Total CD8+T −0.073 0.033 0.026
Total CD4+T −0.132 0.033 6.74 × 10−5
Naïve CD8+T − 0.142 0.033 2.54 × 10−5
Naïve CD4+T −0.072 0.034 0.032
B cell −0.063 0.033 0.052
Natural killer −0.055 0.033 0.094
Senescent CD8+T 0.134 0.033 3.79 × 10−5
Monocytes 0.052 0.034 0.123
Plasmablasts 0.148 0.034 1.38 × 10−5
Granulocytes 0.133 0.033 4.17 × 10−5
Table 3 Baseline and longitudinal associations between log-transformed inflammatory biomarkers and epigenetic age acceleration
IEAA* EEAA†
Standardised beta SE p Standardised beta SE p
Baseline
Low-sensitivity CRP 0.057 0.033 0.087 0.154 0.034 2.48 × 10−5
High-sensitivity CRP 0.047 0.036 0.189 0.111 0.037 0.004
IL-6 0.021 0.036 0.563 0.114 0.037 0.003
Low-sensitivity CRP ≤ 10 mg/L 0.062 0.035 0.081 0.129 0.039 0.0009
Longitudinal
Low-sensitivity CRP −0.017 0.019 0.360 −0.008 0.019 0.672
High-sensitivity CRP 0.005 0.039 0.888 −0.006 0.039 0.888
IL-6 0.034 0.041 0.392 0.009 0.042 0.829
Low-sensitivity CRP ≤ 10 mg/L −0.020 0.020 0.303 −0.006 0.020 0.759
CRP C-reactive protein, IL-6 interleukin 6
*Intrinsic epigenetic age acceleration
†Extrinsic epigenetic age acceleration
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highly fluctuating, levels could exacerbate the risk of dis-
ease. Finally, the mean age of the cohort at wave 1 was 70
years, and it is possible participants had already under-
gone a transition to an increased inflammatory profile and
this is why we did not capture a rise in CRP over time.
This is in line with findings from a previous study which
reported an increased serum level of CRP between a 20–
30-year-old age group and 60–70-year-olds, but no signifi-
cant difference in levels between 60–70-year-olds and the
70–90-year-olds [23].
Because of the complexity in the inflammatory trajec-
tories, and given that adaptive immune dysregulation is
thought to be an important reciprocal mechanism to
age-related inflammation, we additionally examined the
dynamics of the immune cells imputed from the methyla-
tion data, and their association with CRP. It is important
to highlight, however, that whilst we modelled the cell
trajectories, the Houseman algorithm does not quantify
actual cell counts, but instead yields cellular proportions,
and the Horvath method estimates abundances (inter-
preted on an ordinal scale). We therefore cannot defini-
tively establish whether the alterations in their profiles
were due to a true change in the dimensions of the cell
population or were instead a consequential shift due to
alterations in other cell numbers. The baseline associa-
tions between CRP and the cells were not congruent, indi-
cating the relationship between inflammatory mediators
and individual immune cells is not uniform, with different
compartments of the system displaying different relative
characteristics. The interrelationship between inflammation
and the immune system is clearly complex and the dyad is
probably influenced further by other additional pathophysio-
logical pathways activated in older age. Our results fit with
the remodelling theory of ageing which postulates that
immunosenescence or ‘immuno-remodelling’ is a dynamic
process involving both loss and gains of immune function
[21, 24]. This theory hypothesises that those with a superior
capacity to adapt their inflammatory and immune responses,
rather than necessarily generating the most robust response,
age most successfully. Exactly which of these alterations
may be beneficial, and which detrimental, remains to be
determined.
Despite no evidence of an increase in CRP with chrono-
logical age within the cohort, we found positive associa-
tions between all inflammatory biomarkers and extrinsic
epigenetic age acceleration, suggesting a faster running epi-
genetic clock is associated with an increased inflammatory
profile. No parallel association was seen between any of the
inflammatory mediators and the intrinsic (cell-adjusted)
measure of age acceleration. This discordance may be due
to the difference in the two estimates. IEAA is calculated
independently of the blood cellular composition, measures
cell-intrinsic methylation changes, and likely captures an
ageing process that is mostly conserved across cell types.
Contrastingly, EEAA does capture age-related alterations
in leukocyte composition and correlates with health-related
characteristics [25]. Evidently, systemic inflammation is
closely tied to the blood tissue and so is perhaps more
likely to be discerned by a blood-based measure than
one that focuses on multiple tissue types. Our results are
similar to a recent cross-sectional study on a cohort of
middle-aged adults where EEAA was found to correlate
strongly with CRP and IL-6 but no similar association was
found with IEAA [26].
The main strength of this study is its basis in a relatively
large sample of older people with long-term follow-up.
The repeated measures of the serum biomarkers have
permitted both a description of their trajectories across
the eighth decade, and the investigation of longitudinal
associations with biological age. The study may have
been limited by the cohort effect; as discussed above,
the sample is representative of healthier older ageing
and findings may not be relevant to typical ageing in
which multi-morbidity is common. Further investigation
in independent cohorts is necessary to validate these find-
ings. Additionally, we only examined a restricted number
of inflammatory variables and the observed associations
with epigenetic age acceleration do not provide evidence
of causation. As the trajectories of the inflammatory
biomarkers were complex, it is difficult to determine
which is most representative. IL-6, which showed a signifi-
cant increase, may be a more indicative or reliable measure
of inflammation, but as it was only available for two time--
points we focused our analyses on CRP. Recent results
have questioned the utility of DNA methylation pat-
terns as biomarkers of ageing, as a reduced prediction
error of chronological age was found in studies using
larger sample sizes to train the age predictor [27]. These
findings indicate a limitation in the variation in biological
age that is captured by DNA methylation and so caution
is needed in the interpretation of results from epigenetic
age predictors. Finally, we did not apply a correction for
multiple testing. Applying a strict Bonferonni-corrected
threshold of significance would result in the attenuation
of the less highly significant finding of the association
between total CD8+T cells and CRP.
Conclusion
The dynamics of the assessed inflammatory markers did
not conclusively confirm an increased inflammatory
state with older chronological age. We found, however,
that a faster running epigenetic clock, as measured by
extrinsic epigenetic age acceleration, associated with a
raised inflammatory profile cross-sectionally. This associ-
ation should be investigated further in other independent
populations and with respect to causal inference. The
relationship between CRP and imputed immune cell
counts suggest a divergent association between
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inflammatory mediators and immune parameters. Whether
these are adaptive responses or detrimental changes is un-
clear and should be addressed by future studies.
Methods
The Lothian Birth Cohort 1936 (LBC1936)
Details of the LBC1936 study have been described previ-
ously [28]. Briefly, the cohort comprises individuals born
in 1936, most of whom who took part in the Scottish
Mental Survey 1947, aged about 11 years. One thousand
and ninety-one participants were recruited to the study
at a mean age of 70 years and, to date, have completed
up to four waves of testing at mean ages of 70, 73, 76
and 79. Data collection for wave 5 is ongoing [29]. At each
wave, participants have been extensively phenotyped with
data obtained on a wide range of health outcomes, lifestyle
factors, psycho-social variables, genetics and epigenetics,
and cognition.
CRP and IL-6
Serum CRP (mg/L) and IL-6 (pg/ml) were measured from
venesected whole-blood samples. CRP levels were quanti-
fied using both a regular-sensitivity assay (low-sensitivity
CRP) at all four waves of data collection, and a high-sensi-
tivity assay (high-sensitivity CRP) at waves 2 and 3. The
low-sensitivity assay was performed using a dry-slide
immuno-rate method on an OrthoFusion 5.1 F.S analysers
(Ortho Clinical Diagnostics). This assay cannot distinguish
values less than 3mg/L, and all readings less than 3mg/L
were assigned a value of 1.5 mg/L. The high-sensitivity
assay was performed at the University of Glasgow using
an enzyme-linked immunosorbent assay (ELISA; R&D
Systems, Oxford, UK) [30]. Though the high-sensitivity
assay is more accurate and would have been preferred in
analysis, more longitudinal data was available from the
lower-sensitivity assay, so both measures were included to
establish the equivalence in their trajectories and associa-
tions with epigenetic age. IL-6 levels were determined
using high-sensitivity ELISA kits (R&D Systems, Oxford,
UK) at waves 2 and 3 [31].
To account for skewed distributions, both CRP and
IL-6 levels were log-transformed (natural log) prior to
analyses.
Cell counts
Blood cell proportions were estimated based on DNA
methylation signatures as described by Chen et al. [16].
Briefly, two approaches were used: Houseman’s estimation
method and the Horvath method. Houseman’s method
uses methylation signatures from purified leukocytes to
estimate the proportion of CD8+T cells, CD4+T cells,
natural killer cells, B cells, monocytes and granulocytes
[32]. The Horvath method, calculated via the advanced
analysis option of the epigenetic age calculator software,
was used to estimate the ordinal abundance of exhausted/
senescent CD8+T cells, naïve CD4+T and CD8+T cells and
plasmablasts [11, 33]. Imputed cell counts have been shown
to have a moderate correlation with reciprocal flow cyto-
metric data [34].
Epigenetic age acceleration
Methodological details of the methylation profiling for
LBC1936 are provided in (Additional file 2).
Age acceleration was calculated for each subject at
each wave using the online calculator developed by Horvath
(https://dnamage.genetics.ucla.edu/) [11].
Two established measures of methylation-based age
acceleration were used in this study: intrinsic epigenetic
age acceleration (IEAA) and extrinsic epigenetic age accel-
eration (EEAA). IEAA, based on methylation at 353 CpG
sites across multiple tissues as described by Horvath,
captures ‘pure’, cell-intrinsic epigenetic ageing, independent
of age-related changes in blood cell composition [11]. It is
defined as the residual resulting from a multivariate regres-
sion model of Horvath methylation age on chronological
age and estimates of various blood immune cell counts
imputed from methylation data.
Conversely, EEAA, an enhanced version of the Hannum
clock based on 71 CpGs, up-weights the contribution of
immune blood cell counts, in addition to tracking intrinsic
methylation changes [12]. EEAA is calculated through use
of a weighted average of Hannum’s methylation age with
three cell types that are known to change with age—naïve
cytotoxic T cells, exhausted cytotoxic T cells and plasma-
blasts—using the Klerma-Doubal approach [35]. EEAA is
defined as the residual variation resulting from regressing
the weighted estimated age on chronological age [16].
Statistical analysis
Linear mixed models were used to investigate the baseline
relationship between the inflammatory biomarker levels
and the imputed cell counts and epigenetic age acceler-
ation measures independently. In each model, age, sex
and anti-inflammatory drug status (collected at baseline
and coded as a dichotomous variable: on medication = 1;
not on medication = 0) were included as covariates. Batch
effects (set, position, array, plate and date) were included
as random effects to control for technical artefacts.
Mixed effect models were used to examine the longitu-
dinal change in cell counts and inflammatory biomarkers
over the four waves for the low-sensitivity CRP, and two
waves for the high-sensitivity CRP and IL-6. Here, sex and
baseline use of anti-inflammatory medication were included
as covariates, and age (years) as the timescale. Partici-
pant ID and batch effects were fitted as random effects
on the intercept. Interaction terms (between chrono-
logical age and baseline epigenetic age acceleration, both
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centred to have mean 0 and SD 1) were included to inves-
tigate the changes in inflammatory biomarker levels with
age predicted by baseline epigenetic age acceleration. Thus,
the model formula was the following: inflammatory_bio-
marker ~ age*baseline_DNAm_age + sex + anti_inflam-
matory_status + (1|ID) + (1|set) + (1|date) + (1|array)
+ (1|position) + (1|plate).
Pearson correlations were calculated between IL-6 and
the high- and low-sensitivity CRP measures, and between
low-sensitivity CRP and the imputed cell counts at each
wave separately.
Analyses were performed in R Version 3.5.0 using the
‘lmerTest’ library (Version 3.0–1) [36, 37].
Additional files
Additional file 1: Table S1. Baseline associations between (low-sensitivity)
C-reactive protein ≤10mg/L and imputed immune cell profiles. (DOCX 14 kb)
Additional file 2: LBC1936 DNA Methylation. DNA methylation profiling
methods of LBC1936. (DOCX 17.9 kb)
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